I medici

Dr. med.
Andrea Azzola

Formazione

Laurea in medicina
1995
Università di Basilea (CH)

Specializzazione

Pneumologia
2005
Medicina intensiva
2005
Medicina interna generale
2003

Ruolo

Specialista in pneumologia, medicina intensiva e medicina interna generale
Medico consulente

Affiliazioni

Federazione dei medici svizzeri (FMH)
Ordine dei medici del Canton Ticino (OMCT)
Società svizzera di pneumologia (SSP), membro del Board dal 2015
Società Svizzera di ipertensione polmonare (SSIP), membro del Board dal 2007, Presidente 2018-2021, attuale - Past president e tesoriere
European Respiratory Society (ERS)
American College of Chest Physician (ACCP), Fellow FCCP dal 2008
Società svizzera di medicina intensiva (SSMI)
Società svizzera di medicina interna generale (SGAIM)

Inizio attività in clinica

2022

Contatto

Ambulatorio di pneumologia
Via Moncucco 10, 6903 Lugano
T+ 41 91 960 85 88
andrea.azzola@moncucco.ch
pneumologia@moncucco.ch

Contatto studio privato

Studio medico WTC Agno
World Trade Center Via Lugano 18 (Blocco 4, 1° piano), 6982 Agno
T+ 41 91 605 37 65

Lingue

Italiano
Tedesco
Francese
Inglese

Esperienze professionali

Attività presso il proprio studio privato - Studio medico WTC di Agno (dal 2022)
Primario di pneumologia presso l’Ospedale cantonale di Lucerna
2019 / 2022
Caposervizio presso l’Ospedale Regionale di Lugano
2006 / 2019
Capoclinica presso l’Ospedale universitario di Basilea
2004 / 2005

Pubblicazioni

The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program Jungblut L, von Garnier C, Puhan M, Tomonaga Y, Kaufmann C, Azzola A, Bürgi U, Bremerich J, Brutsche M, Christe A, Ebner L, Heverhagen JT, Eich C, Franzen D, Schmitt-Opitz I, Schneiter D, Spieldenner J, Horwath N, Kohler M, Weder W, Lovis A, Meuli R, Menig M, Beigelmann-Aubry C, Niemann T, Stöhr S, Vock P, Senn O, Neuner-Jehle S, Selby K, Laures S, Ott S, Frauenfelder T. Swiss Med Wkly. 2022 Apr 14;152(15-16) Impact Factor: 1.821
Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry Appenzeller P, Lichtblau M, Berlier C, Aubert JD, Azzola A, Fellrath JM, Geiser T, Lador F, Pohle S, Opitz I, Schwerzmann M, Stricker H, Tamm M, Saxer S, Ulrich S. Pulm Circ. 2022 Jan 5;12(1):e12001. Impact Factor: 3.017
COVID-19 and the role of imaging: early experiences in Central Switzerland Fechner C, Strobel K, Treumann Th, Sonderegger B, Azzola A, Fornaro J, Schrading S, Roos JE Swiss Med Wkly. 2020 Jun 22;150 Impact Factor: 1.821
Minimum clinically important difference in 30-s Sit-to-Stand test after pulmonary rehabilitation in subjects with COPD Zanini A, Crisafulli E, D'Andria M, Gregorini C, Cherubino F, Zampogna E, Azzola A, Spanevello A, Schiavone N, Chetta A Respir Care. 2019 Jul 3; [Epub ahead of print] Impact Factor: 1.736
Hypertension pulmonaire pour le généraliste en 2018. Azzola A. Rev Med Suisse. 2018 Jan 24;14(591):212-215 Impact Factor: 0.12
Multicenter, observational screening survey for the detection of chronic thromboembolic pulmonary hypertension following pulmonary embolism Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, Stricker H, Pagnamenta A, Ott S, Ulrich S, Györik S, Aubert JD Eur Respir J. 2018 Apr 4;51(4) Impact Factor: 19.287
Development and initial evaluation of a novel ultra-portable virtual reality bronchoscopy simulator: the Computer Airway Simulation System (CASS Simulator). Casso G, Schoettker P, Savoldelli GL, Azzola A, Cassina T Anesth Analg. 2018 Feb 23 Impact Factor: 3.463
Modern invasive hemodynamic assessment of pulmonary hypertension Pagnamenta A, Lador F, Azzola A, Beghetti M Respiration. 2018;95(3):201-211. Impact Factor: 2.651
Invasive hemodynamic evaluation of the pulmonary circulation in pulmonary hypertension Pagnamenta A, Azzola A, Beghetti M, Lador F; on behalf of The Swiss Society of Pulmonary Hypertension) Swiss Med Wkly. 2017 Jul 19;147 Impact Factor: 1.823
Idiopathic pulmonary fibrosis in Switzerland - Diagnosis and Treatment. Position of the Working Group for Interstitial and rare lung diseases of the Swiss Respiratory Society Funke-Chambour M., Azzola A., Adler D., Barazzone-Argiroffo C., Benden C., Boehler A., Bridevaux P.-O., Brutsche M., Clarenbach C., Hostettler K., KleinerFinger R., Nicod L.P., Soccal P.M., Tamm M., Geiser T,, Lazor R Respiration. 2017; 93(5):363-378 Impact Factor: 2.651
3. Indacaterol and Glycopyrronium versus Indacaterol on Body Plethysmography Measurements in COPD - A randomised controlled study Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; Azzola A; Sigrist Th; Fitting JW; Schmidt U; Geiser Th; Wild C; Kostikas K; Clemens A; Brutsche M Respiratory Research 2017;18:13 Impact Factor: 3.751
. The one repetition maximum test and the sit-to-stand test in the assessment of a specific pulmonary rehabilitation program on peripheral muscle strength in COPD patients. Zanini A, Aiello M,Cherubino F, Zampogna E, Azzola A, Chetta A, Spanevello A. Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2423-30 Impact Factor: 3.046
Extra-anatomical VATS lung resection: the outpatient experience with the aid of a digital chest drain device. Cafarotti S, Cusumano G, Giuliani M, Matarelli E, Carboni GL, Schneiter D, Azzola A*- Pneumoclub Ticino CH*, Dutly AE (*member of). Eur Rev Med Pharmacol Sci. 2015 Oct;19(20):3850-4. Impact Factor: 1.575
. Long-term data from the Swiss pulmonary hypertension registry. Mueller-Mottet S, Stricker H, Domenighetti G, Azzola A, Geiser T, Schwerzmann M, Weilenmann D, Schoch O, Fellrath JM, Rochat T, Lador F, Beghetti M, Nicod L, Aubert JD, Popov V, Speich R, Keusch S, Hasler E, Huber LC, Grendelmeier P, Tamm M, Ulrich S. Respiration. 2015;89(2):127-40 Impact Factor: 2.651
Oxygen kinetics during 6-minute walk tests in patients with cardiovascular and pulmonary disease. Kern L, Condrau S, Baty F, Wiegand J, van Gestel AJ, Azzola A, Tamm M, Brutsche M. BMC Pulm Med. 2014 Oct 29;14:167 Impact Factor: 2.329
Sleep-disordered breathing in acute ischemic stroke and transient ischemic attack: effects on short- and long-term outcome and efficacy of treatment with continuous positive airways pressure--rationale and design of the SAS CARE study. Cereda CW, Petrini L, Azzola A, Ciccone A, Fischer U, Gallino A, Györik S, Gugger M, Mattis J, Lavie L, Limoni C, Nobili L, Manconi M, Ott S, Pons M, Bassetti CL. Int J Stroke. 2012 Oct;7(7):597-603 Impact Factor: 3.044
Therapeutic bronchoscopy for malignant airway stenoses: choice of modality and survival. Chhajed PN, Somandin S, Baty F, Mehta AJ, Azzola A, Leuppi J, Tamm M, Brutsche MH. J Cancer Res Ther. 2010 Apr-Jun;6(2):204-9. Impact Factor: 0.825
Fatal cerebral air embolism following uneventful flexible bronchoscopy. Azzola A, von Garnier C, Chhajed PN, Schirp U, Tamm M. Respiration. 2010;80(6):569-72. Impact Factor: 2.651
Six-minute walk test enhanced by mobile telemetric cardiopulmonary monitoring. Tueller C, Kern L, Azzola A, Baty F,Condrau S,Wiegand J,Tamm M, Brutsche M. Respiration. 2010;80(5):410-8. Impact Factor: 2.651
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M. Eur Respir J. 2009 Dec;34(6):1364-75. Impact Factor: 8.332
Therapeutic bronchoscopy interventions before surgical resection of lung cancer. Chhajed PN, Eberhardt R, Dienemann H, Azzola A, Brutsche MH, Tamm M, Herth FJ. Ann Thorac Surg. 2006 May;81(5):1839-43. Impact Factor: 2.975
Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection. Azzola A, Passweg JR, Habicht JM, Bubendorf L, Tamm M, Gratwohl A, Eich G. J Clin Microbiol. 2004 Oct;42(10):4805-8. Impact Factor: 3.631
Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P, Roth M, Glanville A, Tamm M. Transplantation. 2004 Jan 27;77(2):275-80. Impact Factor: 3.69